Dr. Reddy’s announces positive topline results from phase 2b study of PPC-06 in moderate to severe plaque psoriasis

This article was originally published here

In the study, PPC-06 met both co-primary endpoints i.e. PASI-75 and IGA scores of 0 or 1 with at least a 2-point reduction from baseline, after 24 weeks

The post Dr. Reddy’s announces positive topline results from phase 2b study of PPC-06 in moderate to severe plaque psoriasis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply